Simon Dumesnil bought KTTA once, on Nov 28, 2025

Simon Dumesnil is an independent director of Pasithea Therapeutics Corp. (NASDAQ: KTTA), serving on the company’s board since April 2021.( In this role he contributes expertise in distressed investing, structured finance, and corporate restructuring, including service on a special committee of independent directors formed in 2023 to evaluate an unsolicited acquisition proposal.( As a Pasithea insider, he has been granted equity compensation under the company’s 2023 Stock Incentive Plan and has purchased Pasithea common stock on the open market, reflecting a direct alignment with shareholder interests.(

Dumesnil is Managing Partner and Director of Dunraven Capital Partners Limited, a UK-based investment management advisory firm focused primarily on Eastern European corporate distressed credits and structured products.( Previously, he was Managing Director and Head of the Structured Financing Group Americas at UBS Securities LLC, overseeing a U.S. and Latin American structured financing trading book across a range of fixed income products, and held senior structuring roles at UBS AG in EMEA.( He has also served as Chief Investment Officer at Bluestone Capital Management Ltd., investing in distressed assets across Europe, and as a director at Lehman Brothers International (Europe) and Lehman Brothers Holding Inc., where he worked on restructuring and unwinding Lehman Brothers Special Financing Inc.’s derivative book following the firm’s bankruptcy.( Dumesnil holds a Master of Science in Banking and International Finance from Cass (Bayes) Business School and a Bachelor’s degree in Business Administration and Finance from École des Hautes Études Commerciales (HEC) Paris.(

Written by Perplexity from public sources.